AbbVie (ABBV) said Friday it received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of its Rinvoq drug for the treatment of giant cell arteritis in adults.
The positive opinion is based on results from the company's phase 3 clinical trial evaluating the efficacy and safety of the drug. The primary endpoint of sustained remission and important secondary endpoints of the study were met, AbbVie said.
The company anticipates final approval from the European Commission for the product in the first half of 2025.
Giant cell arteritis is an inflammatory disease that can result in blindness and stroke if left untreated, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。